The endocannabinoid system in targeting inﬂammatory neurodegenerative diseasesDiego Centonze 1,2, Alessandro Finazzi-Agro`3, Giorgio Bernardi 1,2 and Mauro Maccarrone 2,4
1 Neurological Clinics, Department of Neurosciences, University of Rome Tor Vergata, Rome 00133, Italy 2 European Center for Brain Research (CERC) and Santa Lucia Foundation, Rome 00196, Italy 3 Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome 00133, Italy 4 Department of Biomedical Sciences, University of Teramo, Teramo 64100, Italy
ScienceDirect 2007, doi:10.1016/j.tips.2007.02.00
The classical divide between degenerative and inﬂammatory disorders of the CNS is vanishing as accumulating evidence shows that inﬂammatory processes are important in the pathophysiology of primarily degenerative disorders, and neurodegeneration complicates primarily inﬂammatory diseases of the brain and spinal cord. Here, we review the contribution of degenerative and inﬂammatory processes to CNS disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis and HIV-associated dementia. An early combination of neuroprotective and anti inﬂammatory approaches to these disorders seems particularly desirable because isolated treatment of one pathological process might worsen another. We also discuss the apparently unique opportunity to modify neurodegeneration and neuroinﬂammation simultaneously by pharmacological manipulation of the endocannabinoid system in the CNS and in peripheral immune cells. Current knowledge of this system and its involvement in the above CNS disorders are also reviewed.
Full Source with Visuals: The endocannabinoid system in targeting inﬂammatory neurodegenerative diseases